216 related articles for article (PubMed ID: 8581382)
1. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Chamow SM; Zhang D; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
J Hematother; 1995 Oct; 4(5):439-46. PubMed ID: 8581382
[TBL] [Abstract][Full Text] [Related]
2. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Chamow SM; Zhang DZ; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
J Immunol; 1994 Nov; 153(9):4268-80. PubMed ID: 7930627
[TBL] [Abstract][Full Text] [Related]
3. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HSV-1-specific cytotoxic T lymphocytes by recombinant-derived gp120 of HIV-1.
Schmid DS; Thieme ML; Ridgeway MR; Mawle AC
Viral Immunol; 1992; 5(4):249-56. PubMed ID: 1361737
[TBL] [Abstract][Full Text] [Related]
5. Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules.
Pollara J; Edwards RW; Jha S; Lam CK; Liu L; Diedrich G; Nordstrom JL; Huffman T; Pickeral JA; Denny TN; Permar SR; Ferrari G
Front Immunol; 2020; 11():713. PubMed ID: 32373131
[TBL] [Abstract][Full Text] [Related]
6. Janusin: new molecular design for bispecific reagents.
Traunecker A; Lanzavecchia A; Karjalainen K
Int J Cancer Suppl; 1992; 7():51-2. PubMed ID: 1428404
[TBL] [Abstract][Full Text] [Related]
7. Lysis of cells infected with HIV-1 by human lymphocytes targeted with monoclonal antibody heteroconjugates.
Zarling JM; Moran PA; Grosmaire LS; McClure J; Shriver K; Ledbetter JA
J Immunol; 1988 Apr; 140(8):2609-13. PubMed ID: 2965725
[TBL] [Abstract][Full Text] [Related]
8. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
9. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.
Tyler DS; Nastala CL; Stanley SD; Matthews TJ; Lyerly HK; Bolognesi DP; Weinhold KJ
J Immunol; 1989 Feb; 142(4):1177-82. PubMed ID: 2536767
[TBL] [Abstract][Full Text] [Related]
10. Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets.
Smyth MJ; Norihisa Y; Ortaldo JR
J Immunol; 1992 Jan; 148(1):55-62. PubMed ID: 1345790
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
12. CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients.
Amadori A; De Silvestro G; Zamarchi R; Veronese ML; Mazza MR; Schiavo G; Panozzo M; De Rossi A; Ometto L; Mous J
J Immunol; 1992 May; 148(9):2709-16. PubMed ID: 1374095
[TBL] [Abstract][Full Text] [Related]
13. Resting human peripheral blood lymphocytes can be activated to cytolytic function by antibodies to CD3 in the absence of exogenous interleukin-2.
Scott CF; Lambert JM; Bolender S; Blattler WA
Cell Immunol; 1988 Jul; 114(2):370-84. PubMed ID: 3260543
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of NK cell-mediated antibody-dependent lysis of recombinant gp120-coated CD4 cells by complement.
Parker SJ; Sadlon TA; Gordon DL
J Infect Dis; 1995 Jan; 171(1):186-9. PubMed ID: 7798661
[TBL] [Abstract][Full Text] [Related]
16. Biological properties of a CD4 immunoadhesin.
Byrn RA; Mordenti J; Lucas C; Smith D; Marsters SA; Johnson JS; Cossum P; Chamow SM; Wurm FM; Gregory T; Groopman JE; Capon DJ
Nature; 1990 Apr; 344(6267):667-70. PubMed ID: 1970124
[TBL] [Abstract][Full Text] [Related]
17. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
[TBL] [Abstract][Full Text] [Related]
18. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen.
Phillips JH; Lanier LL
J Immunol; 1986 Mar; 136(5):1579-85. PubMed ID: 2419407
[TBL] [Abstract][Full Text] [Related]
19. Primary cytotoxicity against the envelope glycoprotein of human immunodeficiency virus-1: evidence for antibody-dependent cellular cytotoxicity in vivo.
Tanneau F; McChesney M; Lopez O; Sansonetti P; Montagnier L; Rivière Y
J Infect Dis; 1990 Oct; 162(4):837-43. PubMed ID: 1698205
[TBL] [Abstract][Full Text] [Related]
20. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
